aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail
Despite missing the primary endpoint, aTyr Pharma still sees a future for the drug as it plans further FDA discussions.
16 September 2025
16 September 2025
Despite missing the primary endpoint, aTyr Pharma still sees a future for the drug as it plans further FDA discussions.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.